Skip to content

SeraCare Life Sciences, Inc.

SERA position long Ken Shubin Stein

Thesis

SeraCare was interesting and relatively straightforward in terms of the work, and we understood how the issues applied to the company and why it was protected from a lot of challenges in the healthcare industry, making it undervalued enough that it was a good investment.

Did it work?

inconclusive confidence: low

The pitch is a general undervaluation thesis for SeraCare with no stated catalyst, target price, or horizon, and no price performance or elapsed time data is available. Without either a measurable return or a specific thesis event to verify, there is no basis to judge whether the undervaluation was realized. The verdict must remain inconclusive.